ABBV · News · 20261107N
Licensing / Collaboration Deals
AbbVie Inc. · 2026-11-07 · Importance 50 · Surprise 42 · No source text
AbbVie agreed to a global licensing deal with Nxera Pharma for an oral EP4 receptor agonist targeting inflammatory bowel disease, with payments and other deal value of up to US$1.37 billion. AbbVie receives worldwide development and commercialization rights, while Nxera retains certain co-funding and royalty interests. The report also notes AbbVie’s UK research expansion, including a new Oxford facility focused on immunology, neuroscience, and oncology programs.
Key facts
- AbbVie agreed to a global licensing deal with Nxera Pharma for an oral EP4 receptor agonist targeting inflammatory bowel disease, worth up to US$1.37 billion, giving AbbVie worldwide development and commercialization rights. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| liability | negative | contingent | -0.1% | AbbVie agreed to a global licensing deal with Nxera Pharma for an oral EP4 receptor agonist targeting inflammatory bowel disease, worth up… |